Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 845,691
  • Shares Outstanding, K 48,743
  • Annual Sales, $ 15,840 K
  • Annual Income, $ -308,480 K
  • EBIT $ -200 M
  • EBITDA $ -188 M
  • 60-Month Beta 0.89
  • Price/Sales 53.63
  • Price/Cash Flow N/A
  • Price/Book 15.21

Options Overview Details

View History
  • Implied Volatility 65.34% ( -4.00%)
  • Historical Volatility 233.30%
  • IV Percentile 21%
  • IV Rank 31.91%
  • IV High 180.71% on 07/03/24
  • IV Low 11.27% on 05/07/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 567
  • Volume Avg (30-Day) 5,430
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 60,526
  • Open Int (30-Day) 55,699

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.44
  • Number of Estimates 5
  • High Estimate 1.14
  • Low Estimate -1.00
  • Prior Year -1.53
  • Growth Rate Est. (year over year) +71.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.85 +196.58%
on 11/25/24
18.12 -4.25%
on 12/24/24
+11.57 (+200.17%)
since 11/22/24
3-Month
4.45 +289.89%
on 10/03/24
18.12 -4.25%
on 12/24/24
+12.21 (+237.55%)
since 09/24/24
52-Week
3.73 +365.15%
on 07/05/24
18.12 -4.25%
on 12/24/24
+11.03 (+174.53%)
since 12/22/23

Most Recent Stories

More News
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?

Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's...

QURE : 17.35 (-0.46%)
uniQure Announces FDA Agreement on Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

The FDA supports uniQure's AMT-130 for Huntington's disease under an Accelerated Approval pathway using existing study data.Quiver AI SummaryuniQure N.V. announced that the U.S. Food and Drug Administration...

QURE : 17.35 (-0.46%)
uniQure Stock Hits 18-Month High After FDA Agreement Clears Pathway For Huntington’s Treatment: Retail Gets More Optimistic

uniQure’s AMT-130 previously received a regenerative medicine advanced therapy designation from the FDA in May.

QURE : 17.35 (-0.46%)
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

QURE : 17.35 (-0.46%)
uniQure N.V. Initiates Phase I/IIa Clinical Trial for AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

uniQure initiates GenTLE trial, dosing first patient with AMT-260 for refractory mesial temporal lobe epilepsy treatment.Quiver AI SummaryuniQure N.V. announced the dosing of the first patient in its GenTLE...

QURE : 17.35 (-0.46%)
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

QURE : 17.35 (-0.46%)
UniQure: Q3 Earnings Snapshot

UniQure: Q3 Earnings Snapshot

QURE : 17.35 (-0.46%)
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

QURE : 17.35 (-0.46%)
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

QURE : 17.35 (-0.46%)
UniQure: Q2 Earnings Snapshot

UniQure: Q2 Earnings Snapshot

QURE : 17.35 (-0.46%)

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 19.35
2nd Resistance Point 18.74
1st Resistance Point 18.04
Last Price 17.35
1st Support Level 16.73
2nd Support Level 16.12
3rd Support Level 15.42

See More

52-Week High 18.12
Last Price 17.35
Fibonacci 61.8% 12.62
Fibonacci 50% 10.93
Fibonacci 38.2% 9.23
52-Week Low 3.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar